Lifetime Risks, Life Expectancy, and Health Care Expenditures for Rheumatoid Arthritis: A Nationwide Cohort Followed Up From 2003 to 2016
Arthritis & Rheumatology2020Vol. 73(5), pp. 750–758
Citations Over TimeTop 10% of 2020 papers
Abstract
Our findings indicate that since biologics became available, RA patients have lived longer and had higher lifetime expenditures, which should be monitored and evaluated for cost-effectiveness.
Related Papers
- → Trace elements and disease activity score in patients with rheumatoid arthritis(2003)10 cited
- Rheumatoid arthritis and astercantha longifolia.(1999)
- [Radiosynoviorthese in the treatment of patients with rheumatoid arthritis].(1990)
- → THE ASSESSMENT OF PRIORITIES FOR INCREASING LIFE EXPECTANCY IN RUSSIA(2014)